Overview Dividends

(MLYS) Mineralys Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6031701013

Phase II Inhibitor, Oral, Cardiorenal

EPS (Earnings per Share)

EPS Growth (3y CAGR): 191.41%
EPS Trend (3y Corr): 9.6%

Last SUE: 0.66σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): 21.8%

Last SUE: 0.00σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	74.8%
Value at Risk 5%th	111%
Relative Tail Risk	-9.98%

Reward TTM
Sharpe Ratio	1.43
Alpha	259.62

Character TTM
Hurst Exponent	0.411
Beta	0.428
Beta Downside	-0.025

Drawdowns 3y
Max DD	68.86%
Mean DD	30.66%
Median DD	30.04%

Description: MLYS Mineralys Therapeutics November 16, 2025

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a U.S. clinical-stage biopharma focused on diseases driven by excess aldosterone. Its lead asset, lorundrostat, is an oral, highly selective aldosterone-synthase inhibitor being pursued for hypertension, chronic kidney disease (CKD) and obstructive sleep apnea.

The company has launched a Phase 2 trial of lorundrostat in hypertensive patients with stage 2-3b CKD and is advancing a pivotal program for uncontrolled or resistant hypertension. Lorundrostat’s mechanism targets a pathway not addressed by current RAAS blockers, positioning it as a potential differentiated therapy.

Key metrics (as of the most recent filing) include a market-cap of roughly $70 million, cash and equivalents of about $45 million, and a burn rate of ~ $12 million per quarter, giving an estimated runway of 3-4 quarters absent additional financing. The U.S. hypertension market exceeds $30 billion, and the CKD segment is projected to grow at ~ 5 % CAGR, providing a sizable addressable pool for a novel aldosterone-targeted drug.

Sector-wide, biotech R&D spending has risen ~ 8 % YoY, while FDA approval rates for Phase 2-to-Phase 3 transitions in cardiovascular therapeutics hover around 30 %, underscoring the execution risk for Mineralys’s pipeline.

For a deeper, data-driven look at MLYS’s valuation assumptions and comparable peer analysis, you might find the ValueRay platform’s analytical dashboards useful.

MLYS Stock Overview

Market Cap in USD	3,505m
Sub-Industry	Biotechnology
IPO / Inception	2023-02-10
Return 12m vs S&P 500	197%
Analyst Rating	4.75 of 5

MLYS Dividends

Currently no dividends paid

MLYS Growth Ratios

Metric	Value
CAGR 3y	41.52%
CAGR/Max DD Calmar Ratio	0.60
CAGR/Mean DD Pain Ratio	1.35
Current Volume	1616.9k
Average Volume	1243.3k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-171.4m TTM) > 0 and > 6% of Revenue (6% = 2040 TTM)

FCFTA -0.29 (>2.0%) and ΔFCFTA 19.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.29 (>3.0%) and CFO -171.4m <= Net Income -171.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 25.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (70.6m) change vs 12m ago 41.71% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.01% (prev 0.0%; Δ 0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -21.09 (EBITDA TTM -179.8m / Interest Expense TTM -8.53m) >= 6 (WARN >= 3)

Altman Z'' -17.76

(A) 0.96 = (Total Current Assets 599.8m - Total Current Liabilities 23.5m) / Total Assets 599.9m

(B) -0.71 = Retained Earnings (Balance) -424.9m / Total Assets 599.9m

(D) -18.07 = Book Value of Equity -424.9m / Total Liabilities 23.5m

Total Rating: -17.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.97

1. Piotroski 0.0pt

2. FCF Yield -5.21%

3. FCF Margin data missing

4. Debt/Equity data missing

5. Debt/Ebitda 1.21

6. ROIC - WACC (= -57.72)%

7. RoE -48.18%

8. Rev. Trend 21.84%

9. EPS Trend 9.64%

What is the price of MLYS shares?

As of November 21, 2025, the stock is trading at USD 41.87 with a total of 1,616,863 shares traded.
Over the past week, the price has changed by -5.46%, over one month by -5.19%, over three months by +170.48% and over the past year by +232.30%.

Is MLYS a buy, sell or hold?

Mineralys Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MLYS.

Strong Buy: 6
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MLYS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45.8	9.3%
Analysts Target Price	45.8	9.3%
ValueRay Target Price	46.8	11.7%

MLYS Fundamental Data Overview November 16, 2025

Market Cap USD = 3.51b (3.51b USD * 1.0 USD.USD)
P/B = 5.6085
Beta = 0.399
Revenue TTM = 34.0k USD
EBIT TTM = -179.9m USD
EBITDA TTM = -179.8m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -217.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.29b USD (3.51b + (null Debt) - CCE 217.6m)
Interest Coverage Ratio = -21.09 (Ebit TTM -179.9m / Interest Expense TTM -8.53m)
FCF Yield = -5.21% (FCF TTM -171.4m / Enterprise Value 3.29b)
FCF Margin = -504.0k% (FCF TTM -171.4m / Revenue TTM 34.0k)
Net Margin = -504.0k% (Net Income TTM -171.4m / Revenue TTM 34.0k)
Gross Margin = -85.29% ((Revenue TTM 34.0k - Cost of Revenue TTM 63.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.48 (Enterprise Value 3.29b / Total Assets 599.9m)
Interest Expense / Debt = unknown (Interest Expense 1.68m / Debt none)
Taxrate = 100.0% (out of range, set to none) (-177.8m / -177.8m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 25.50 (Total Current Assets 599.8m / Total Current Liabilities 23.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 1.21 (negative EBITDA) (Net Debt -217.6m / EBITDA -179.8m)
Debt / FCF = 1.27 (negative FCF - burning cash) (Net Debt -217.6m / FCF TTM -171.4m)
Total Stockholder Equity = 355.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.56% (Net Income -171.4m / Total Assets 599.9m)
RoE = -48.18% (Net Income TTM -171.4m / Total Stockholder Equity 355.7m)
RoCE = -31.21% (EBIT -179.9m / Capital Employed (Total Assets 599.9m - Current Liab 23.5m))
RoIC = -50.13% (negative operating profit) (EBIT -179.9m / (Assets 599.9m - Curr.Liab 23.5m - Cash 217.6m))
WACC = 7.59% (E(3.51b)/V(3.51b) * Re(7.59%) + (debt-free company))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 213.0%
Fair Price DCF = unknown (Cash Flow -171.4m)
EPS Correlation: 9.64 | EPS CAGR: 191.4% | SUE: 0.66 | # QB: 0
Revenue Correlation: 21.84 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for MLYS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle